Feline Mammary Cancer: Novel Nude Mouse Model and Molecular Characterization of Invasion and Metastasis Genes

Veterinary Pathology

Volumn 54, Issue 1, 2017, Pages 32-43

  Hassan, B B ^a,b   Elshafae, S M ^a,c   Supsavhad, W ^a   Simmons, J K ^a   Dirksen, W P ^a   Sokkar, S M ^b   Rosol, T J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Cairo University   (Egypt)

^c Benha University   (Egypt)

Author keywords

angiogenesis; animal model; bone; brain; cat; lung; lymphangiogenesis; mammary cancer; metastasis

Indexed keywords

ANIMAL; CANCER TRANSPLANTATION; CAT; CAT DISEASE; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; CAT DISEASES; CATS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE, NUDE; NEOPLASM TRANSPLANTATION; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 85006750956     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985816650243     Document Type: Article

References (62)

1. Achen MG, Jeltsch M, Kukk E. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95(2):548–553.
2. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002;1(3):219–227.
3. Amatschek S, Koenig U, Auer H. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res. 2004;64(3):844–856.
4. Bergkvist GT, Argyle DJ, Pang LY. Studies on the inhibition of feline EGFR in squamous cell carcinoma: enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors. Cancer Biol Ther. 2011;11(11):927–937.
5. Boyde A, Maconnachie E, Reid SA. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc. 1986(pt 4):1537–1554.
6. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer. 2005;5(9):735–743.
7. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61–66.
8. Davis S, Aldrich TH, Jones PF. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87(7):1161–1169.
9. De Maria R, Maggiora P, Biolatti B. Feline STK gene expression in mammary carcinomas. Oncogene. 2002;21(11):1785–1790.
10. De Maria R, Olivero M, Iussich S. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005;65(3):907–912.
11. DeRose YS, Wang G, Lin YC. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17(11):1514–1520.
12. Diel IJ, Solomayer EF, Costa SD. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339(6):357–363.
13. Egenvall A, Bonnett BN, Häggström J. Morbidity of insured Swedish cats during 1999–2006 by age, breed, sex, and diagnosis. J Feline Med Surg. 2010;12(12):948–959.
14. Egenvall A, Nødtvedt A, Häggström J. Mortality of life-insured Swedish cats during 1999–2006: age, breed, sex, and diagnosis. J Vet Intern Med. 2009;23(6):1175–1183.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–410.
16. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967–974.
17. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
18. Goldstein RH, Weinberg RA, Rosenblatt M. Of mice and (wo)men: mouse models of breast cancer metastasis to bone. J Bone Miner Res. 2010;25(3):431–436.
19. Guise TA, Mohammad KS, Clines G. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12(20 pt 2):6213s–6216s.
20. Hahn KA, Bravo L, Avenell JS. Feline breast carcinoma as a pathologic and therapeutic model for human breast cancer. In Vivo. 1994;8(5):825–828.
21. Hayes HM, Milne KL, Mandell CP. Epidemiological features of feline mammary carcinoma. Vet Rec. 1981;108(22):476–479.
22. Hortobagyi GN, Theriault RL, Porter L. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335(24):1785–1791.
23. Iorns E, Drews-Elger K, Ward TM. A new mouse model for the study of human breast cancer metastasis. PLoS One. 2012;7(10):e47995.
24. Jeltsch M, Kaipainen A, Joukov V. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276(5317):1423–1425.
25. Jemal A, Murray T, Samuels A. Cancer statistics, 2003. CA Cancer J Clin. 2003;53(1):5–26.
26. Joukov V, Pajusola K, Kaipainen A. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15(7):1751.
27. Kim JB, O’Hare MJ, Stein R. Models of breast cancer: is merging human and animal models the future? Breast Cancer Res. 2004;6(1):22–30.
28. Krishnan J, Kirkin V, Steffen A. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 2003;63(3):713–722.
29. Lee J, Gray A, Yuan J. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci U S A. 1996;93(5):1988–1992.
30. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev. 1990;9(2):125–136.
31. Maisonpierre PC, Suri C, Jones PF. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55–60.
32. Matsumoto M, Roufail S, Inder R. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis. 2013;30(6):819–832.
33. Mattila MM, Ruohola JK, Karpanen T. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer. 2002;98(6):946–951.
34. Mauldin GN, Matus RE, Patnaik AK. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med. 1988;2(2):60–65.
35. Mills SW, Musil KM, Davies JL. Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis. Vet Pathol. 2015;52(2):238–249.
36. Misdorp W. Tumors of the mammary gland. In: Meuten DJ, ed. Tumors in Domestic Animals. Ames, Iowa: Iowa State Press; 2008:575–606.
37. Misdorp W, Else RW, HellménLipscomb TP. Histological Classification of Mammary Tumors of the Dog and the Cat. 2nd series. vol 38. Washington, DC: Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology; 1999.
38. Moulton JE. Tumors in Domestic Animals. Berkeley, CA: University of California Press; 1990.
39. Newby JC, Johnston SR, Smith IE. Expression of epidermal growth factor receptor and c-ERBB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 1997;3(9):1643–1651.
40. Normanno N, Bianco C, De Luca A. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003;10(1):1–21.
41. Normanno N, Bianco C, Strizzi L. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005;6(3):243–257.
42. Peto R, Boreham J, Clarke M. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000;355(9217):1822.
43. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature. 1980;283(5743):139–146.
44. Rashid OM, Nagahashi M, Ramachandran S. Is tail vein injection a relevant breast cancer lung metastasis model? J Thorac Dis. 2013;5(4):385–392.
45. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–1664.
46. Rosol TJ, Tannehill-Gregg SH, LeRoy BE. Animal models of bone metastasis. Cancer. 2003;97(3 suppl):748–757.
47. Salomon DS, Brandt R, Ciardiello F. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183–232.
48. Sasaki A, Boyce BF, Story B. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995;55(16):3551–3557.
49. Sfiligoi C, de Luca A, Cascone I. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer. 2003;103(4):466–474.
50. Siegel R, Ward E, Brawley O. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236.
51. Simmons JK, Hildreth BE, Supsavhad W. Animal models of bone metastasis. Vet Pathol. 2015;52(5):827–841.
52. Skobe M, Hawighorst T, Jackson DG. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7(2):192–198.
53. Suri C, Jones PF, Patan S. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1171–1180.
54. Tannehill-Gregg SH, Levine AL, Nadella MV. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis. 2006;23(1):19–31.
55. Uyama R, Hong SH, Nakagawa T. Establishment and characterization of eight feline mammary adenocarcinoma cell lines. J Vet Med Sci. 2005;67(12):1273–1276.
56. Valenzuela DM, Griffiths JA, Rojas J. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A. 1999;96(5):1904–1909.
57. Volakis LI, Li R, Ackerman WE. Loss of myoferlin redirects breast cancer cell motility towards collective migration. PLoS One. 2014;9(2):e86110.
58. Weijer K, Head KW, Misdorp W. Feline malignant mammary tumors, I: morphology and biology: some comparisons with human and canine mammary carcinomas. J Natl Cancer Inst. 1972;49(6):1697–1704.
59. Werbeck JL, Thudi NK, Martin CK. Tumor microenvironment regulates metastasis and metastasis genes of mouse MMTV-PymT mammary cancer cells in vivo. Vet Pathol. 2014;51(4):868–881.
60. Yancopoulos GD, Davis S, Gale NW. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242–248.
61. Zappulli V, De Zan G, Cardazzo B. Feline mammary tumours in comparative oncology. J Dairy Res. 2005;72(S1):98–106.
62. Zappulli V, Rasotto R, Caliari D. Prognostic evaluation of feline mammary carcinomas: a review of the literature. Vet Pathol. 2015;52(1):46–60.